atezolizumab,cabozantinib
roche
['contact03', 'kudos']
the #oncoalerttoptweet day 4 of #asco23 tweet by our faculty results from #contact03 are out both #asco23 and . the 1 st phase 3 trial to assess the efficacy of rechallenge with anti-pdl1 in any cancer type. kudos to , 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨